Implementation research/real life assessment of existing interventions in women and children’s health
Programme Category
Programme Name
Programme Description
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3) builds on the first and second European and Developing Countries Clinical Trials Partnership programmes. This new joint undertaking (JU) is a partnership between the EU and the EDCTP Association, whose members are several European and African countries. The partnership will deliver new solutions for reducing the burden of infectious diseases in SSA and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and across the world.
Identifier Code
Call
Summary
This topic is focused on the need for critical appraisal of existing health interventions, which may have been introduced and used by healthcare systems without rigorous evaluation in clinical trials. It is thus important to understand whether such interventions lead to better overall health in these populations.
Concerted efforts are needed to increase access to potentially lifesaving, cost-effective interventions to prevent and treat PRDs and other diseases such as diarrhoeal diseases, bacterial infections (especially those where antimicrobial resistance is an issue), sepsis and lower respiratory tract infections in pregnant women, newborns, and children to ensure solid evidence is produced for the recommended interventions and to enhance the use of existing interventions in these populations.
Detailed Call Description
Proposals should address the following activities:
- Carry out registration (phase III) and/or post-registration studies of health technologies that tackle infectious diseases affecting women and children to demonstrate clinical effectiveness;
- Demonstrate the cost-effectiveness of the health technologies being investigated in the relevant populations and communities;
- Identify the barriers to the uptake of the health technologies under investigation and address them in the proposed studies;
- Develop methods that can ensure translating clinical research results into healthcare policy and practice in a SSA setting. These methods should be broadly applicable to improve patients’ quality of life beyond the specific health technology being investigated;
- Early involvement and regular interaction with policy and decision-makers, including end-users, to ensure adoption of the health technology by health systems in SSA.
This call is restricted to the following diseases: HIV, malaria, tuberculosis, diarrhoeal diseases, bacterial infections (especially those where antimicrobial resistance is an issue), sepsis and lower respiratory tract infections.
The research carried out and the health technologies developed in the study should tackle infections affecting the health of pregnant women and children up to five years of age.
Neither pre-clinical research nor early-stage clinical trials in the context of product development are within the scope of this call.
Proposals should present a sound assessment of the feasibility of the proposed work, in particular as regards the proposed clinical interventions. Realistic plans for recruitment of subjects (as part of the clinical trial plan with projected dates) should be presented and documented by demonstrated success from previous studies. The proposals should justify the choice of populations to be enrolled into the interventions. Relevant determining characteristics (such as socio-economic status) also need to be considered.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
Expected EU contribution per project: €4 000 000
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Researchers/Research Centers/Institutions
Eligibility For Participation Notes
Early involvement and regular interaction with policy – and decision-makers, including end-users, to ensure adoption of the health technology by health systems in SSA.
Proposals are expected to come from research consortia with a strong representation of institutions and researchers from African countries, including involvement of franco/lusophone countries where possible and relevant.
Also in line with Article 114 of the Council Regulation 2021/2085, participants will be subject to the following additional exploitation obligations – see page 18 of the Annex 1 of the Global Health EDCTP3 Work Programme 2023: call topics.
Call Opening Date
Call Closing Date
EU Contact Point
EDCTP – Europe Office
Postal and visiting address
Anna van Saksenlaan 51
2593 HW The Hague, The Netherlands
Telephone: +31 70 344 0880
EDCTP – Africa Office
Postal address
P.O. Box 19070, Tygerberg 7505
Cape Town, South Africa
Visiting address
Francie van Zijl Drive,
Parowvallei 7505
Cape Town, South Africa
Telephone: +27 21 938 0690
Fax: +27 21 938 0569
Contact Form in the website